Day: June 8, 2023

The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“EGM”) on Monday, 10 July 2023, at 09:30 a.m. at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 09:00 a.m.NOTIFICATION Shareholders who wish to attend the meeting must:both be recorded in the share register maintained by Euroclear Sweden AB on the record date on Friday, 30 June 2023; and not later than on Tuesday, 4 July 2023 have notified their attendance and possible advisors to the Company; either in writing via letter to Mendus AB (publ), “EGM”, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden, or by e-mail to info@mendus.com.The notification shall include full name, personal/corporate identity number, address, daytime telephone number...

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.As announced through a separate press release, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU) and NorthX Biologics (“NorthX”), a Flerie Invest AB (“Flerie”) portfolio company, have entered into a strategic manufacturing alliance. In connection with this alliance, the Board of Directors of Mendus has resolved on a capital raise of approximately SEK 317 million...

Ad hoc announcement pursuant to Art. 53 LR The closing of the purchase agreement signed on May 12, 2023 was implemented on June 7, 2023. This strategic decision allows Feintool to concentrate on its core business of series parts production. The entrepreneurial orientation of the new owner CERTINA creates best conditions for the capital goods business to further expand its leading position. With the divest of the capital goods business, the Feintool Group has positioned itself as a pure player in the business area of high volume parts production manufactured by the technological processes of fineblanking, forming, and electrolamination stamping. This comprises a portfolio of state-of-the-art tooling solutions across the entire process chain through to innovative product solutions for electric motors. Feintool and the CERTINA GROUP are...

MARLBOROUGH, Mass., June 07, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the pricing of its public offering of 8,700,000 shares of common stock (the “Offering”) at a public offering price of $5.00 per share for gross proceeds of approximately $43.5 million, without giving effect to the underwriting discount and commission as well as estimated expenses payable by Akoya. Akoya has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock at the public offering price. The closing of the Offering is expected to occur on June 12, 2023, subject to the satisfaction of customary closing conditions. Akoya intends to use the net proceeds from the Offering for working capital and general corporate purposes. Morgan...

HighlightsArcher Materials has advanced the room temperature capabilities of its qubit material, achieving unprecedented quantum coherence times. The long coherence times increases the time-window for processing quantum information at room temperature beyond that for any known, similar qubit materials. This milestone, which was previously only achieved at -173°C, means more complex computing applications could potentially be performed in more normal operating environments. Archer is the only ASX listed company and one of a few players in the world developing qubit processor technology.SYDNEY, Australia, June 08, 2023 (GLOBE NEWSWIRE) — Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”), a semiconductor company that advances the quantum computing and medical diagnostics industries, has reached a significant milestone...

GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment. The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a phase 3 trial that assessed the efficacy and safety of Capivasertib–fulvestrant therapy in advanced breast cancer patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) cancer whose disease had progressed during or after aromatase inhibitor therapy. The study demonstrated that Capivasertib–fulvestrant combination therapy...

SINGAPORE, June 07, 2023 (GLOBE NEWSWIRE) — PubMatic, (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, and Telkomsel, the largest mobile network operator in Indonesia, today announced a strategic partnership to provide data-driven digital advertising solutions for brands and agencies in Indonesia. Through the partnership, Telkomsel will make audience segments based on mobile customer insights available to advertisers programmatically through Connect, PubMatic’s audience solution. Connect allows advertisers to engage audiences through privacy-compliant solutions that perform — without relying on third-party cookies or outdated strategies. Furthermore, applying valuable audience segments, such as those from Telkomsel, on the sell-side brings greater efficiency to...

VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the use of its RECELL® System to treat full-thickness skin defects. “This is a landmark approval representing an inflection point for AVITA Medical,” said Jim Corbett, AVITA Medical Chief Executive Officer. “The FDA approval now offers surgeons a best-in-class treatment option for a multitude of severe wounds within inpatient and outpatient settings.” The expanded indication represents a broad label of full-thickness skin defects,...

HOUSTON, June 07, 2023 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc.TM (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”), a leader in the specialty property and casualty (“P&C”) market, today announced the pricing of its underwritten offering of 3,850,000 of its common stock by The Westaim Corporation at the price of $23.00 per share. The Westaim Corporation along with certain other selling shareholders (collectively, the “Selling Stockholders”) also granted the underwriters a 30-day option to purchase up to an additional 577,500 shares of Skyward Specialty’s common stock. Skyward Specialty will not receive any of the proceeds from the sale of the shares of its common stock offered by the Selling Stockholders, and the Selling Stockholders will bear the underwriting discounts and commissions...

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) — Sterling Check Corp. (NASDAQ: STER) (“Sterling”), a leading global provider of technology-enabled background and identity verification services, today announced the pricing of an underwritten secondary public offering (the “Offering”) of 8,000,000 shares of its common stock by certain of its existing stockholders affiliated with The Goldman Sachs Group, Inc. at a price to the public of $12.25 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock. The offering is expected to close on June 12, 2023, subject to the satisfaction of customary closing conditions. Sterling is not selling any shares in the Offering and will not receive any proceeds from the sale of shares by the selling stockholders...